Correction to: Drugs Ther Perspect 2017;33(7):303–10 https://doi.org/10.1007/s40267-017-0419-5
Page 303, column 2, paragraph 1, lines 1–4: the following sentence, which previously read:
Parkinson’s disease (PD), the most common chronic, progressive, neurodegenerative disease, is a manageable, but as yet, incurable disease that increases in prevalence with age [1, 2].
Should read:
Parkinson’s disease (PD), the second most common chronic, progressive, neurodegenerative disease, is a manageable, but as yet, incurable disease that increases in prevalence with age [1, 2].
Page 304, column 1, paragraph 1, lines 1–4: the following text, which previously read:
levodopa and its rapid peripheral metabolism by aromatic L-amino acid decarboxylase to dopamine and by catechol-O-methyltransferase (COMT) to 3 O-methyldopa (3-OMD) [1–3].
Should read:
levodopa and its rapid peripheral metabolism by aromatic L-amino acid decarboxylase to dopamine and by catechol-O-methyltransferase (COMT) to 3 O-methyldopa (3-OMD) [2,3].
Page 306, column 2, paragraph 1, lines 1–2: the following text, which previously read:
Clinician’s Global Impression of Change (PGI-C) and Patient’s Global Impression of Change (PGI-C) in BIPARK I [18].
Should read:
Clinician’s Global Impression of Change (CGI-C) and Patient’s Global Impression of Change (PGI-C) in BIPARK I [18].
Page 308, column 2, paragraph 3, lines 1–8: the following sentence, which previously read:
Opicapone has the advantage of once-daily administration versus frequent administration with second generation COMT inhibitors, with entacapone administered with each levodopa dose (maximum of ≤ 10 doses/day) and tolcapone administered three times daily [1–3]. Tolcapone is also associated with an increased risk of hepatotoxicity (albeit very rare), which limits its use to patients who fail to respond to other COMT inhibitors [1–3].
Should read:
Opicapone has the advantage of once-daily administration versus frequent administration with second generation COMT inhibitors, with entacapone administered with each levodopa dose (maximum of ≤ 10 doses/day) and tolcapone administered three times daily [3]. Tolcapone is also associated with an increased risk of hepatotoxicity (albeit very rare), which limits its use to patients who fail to respond to other COMT inhibitors [3].
Page 309 reference list: Reference 1, which previously read:
1. Samii A, Nutt J, Ransom RR, et al. Parkinson’s disease. Lancet. 2004;2004(362):1783–93
Should read:
1. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;(386):896–912
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1007/s40267-017-0419-5.
Rights and permissions
About this article
Cite this article
Scott, L.J. Correction to: Opicapone in Parkinson’s disease: a profile of its use. Drugs Ther Perspect 34, 41–42 (2018). https://doi.org/10.1007/s40267-017-0461-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-017-0461-3